Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 3Polycythemia Vera 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Primary Myelofibrosis 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Metastatic Gastrointestinal Carcinoid Tumor 1Lymphoma, Non-Hodgkin 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Glioma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × peginterferon alfa-2b × Clear all
NCT00238329 2013-04-08

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
32 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡